Drug Profile
Research programme: paclitaxel nano-emulsion formulation - ADVENTRX Pharmaceuticals
Alternative Names: ANX 513; BTH 013; SDP-013Latest Information Update: 15 Jan 2022
Price :
$50
*
At a glance
- Originator ADVENTRX Pharmaceuticals
- Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Mitosis inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Ovarian cancer
Most Recent Events
- 30 Jan 2007 Preclinical development is ongoing
- 28 Apr 2006 SD Pharmaceuticals has been acquired by ADVENTRX Pharmaceuticals
- 28 Mar 2006 Preclinical trials in Ovarian Cancer in USA (IV)